Abolition of Cyclic Flow Variations in Stenosed, Endothelium‐Injured Coronary Arteries in Nonhuman Primates With a Peptide Fragment (VCL) Derived From Human Plasma von Willebrand Factor–Glycoprotein Ib Binding Domain

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Circulation

• Publication date

  1994-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.90.6.2976PMID 7994845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.

  1992cited by this paper
• Intravenous administration of monoclonal antibody to the platelet GP IIb/IIIa receptor to treat abrupt closure during coronary angioplasty.

  1992cited by this paper
• A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected].

  1992cited by this paper
• Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina.

  1991cited by this paper
• Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli.

  1991cited by this paper
• Inhibition of platelet-vessel wall interaction. Platelet receptors, monoclonal antibodies, and synthetic peptides.

  1990cited by this paper
• Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications

  1989cited by this paper
• Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.

  1988cited by this paper
• Efficient Production of Active Human Manganese Superoxide Dismutase in Escherichia Coli

  1988cited by this paper
• Insights into the pathogenesis of acute ischemic syndromes.

  1988cited by this paper
• A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728.

  1987cited by this paper
• Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.

  1987cited by this paper
• von Willebrand factor and von Willebrand disease.

  1987cited by this paper
• Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes.

  1986influential reference
• Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries.

  1986cited by this paper
• von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.

  1986cited by this paper
• Isolation and characterization of a collagen binding domain in human von Willebrand factor.

  1986cited by this paper
• Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.

  1985cited by this paper
• Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation.

  1985cited by this paper
• Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms.

  1984cited by this paper
• Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.

  1984cited by this paper
• Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate--dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome.

  1978cited by this paper
• Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin

  1976cited by this paper

• Novel Antiplatelet Therapies

  2019cites this paper
• Humanized GPIbα-von Willebrand factor interaction in the mouse.

  2018cites this paper
• Inhibitors of Platelet Adhesion to VWF and Collagen

  2017cites this paper
• Prediction of Molecular Interaction between Platelet Glycoprotein Ibα and von Willebrand Factor using Molecular Dynamics Simulations.

  2016cites this paper
• signaling and GPIb-dependent thrombus formation in vivo Bruton tyrosine kinase is essential for botrocetin/VWF-induced

  2013cites this paper
• Chapter 58 – Novel Antiplatelet Therapies

  2013cites this paper
• von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina

  2013cites this paper
• Cardiovascular Disease: In‐Depth Look

  2011cites this paper
• Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.

  2011cites this paper
• Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

  2011cites this paper
• platelet-vessel wall interaction in health and disease

  2010cites this paper
• Platelet-vessel wall interaction in health and disease.

  2010cites this paper
• Inhibitors of Platelet Adhesion: VWF-GP1b/IX and Collagen-GPVI Inhibitors

  2009cites this paper
• Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779

  2009cites this paper
• Antiplatelet drugs

  2008cites this paper
• The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons

  2008cites this paper
• Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes

  2008cites this paper
• Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa.

  2008cites this paper
• VWF as a Prognostic Marker for Coronary Artery Disease in Initially Healthy Subjects

  2008cites this paper
• Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation.

  2008cites this paper
• The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time

  2007cites this paper
• Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives

  2007cites this paper
• CHAPTER 65 – Experimental Antiplatelet Therapy

  2007cites this paper
• Inhibition of platelet glycoprotein Ib and its antithrombotic potential.

  2007cites this paper
• Hematologic Disease and Heart Disease

  2007cites this paper
• Two novel monoclonal antibodies to VWFA3 inhibit VWF‐collagen and VWF‐platelet interactions

  2007cites this paper
• Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis

  2006cites this paper
• Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

  2006cites this paper
• Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

  2006cites this paper
• Mechanisms of action and targets for actual and future antiplatelet drugs.

  2006cites this paper
• The development and application of an in vitro model of coronary lesion thrombosis

  2005cites this paper
• Pharmacology of platelet adhesion and aggregation.

  2004cites this paper
• The roles of ADP and TXA2 in botrocetin/VWF‐induced aggregation of washed platelets

  2004cites this paper
• New approaches for antithrombotic antiplatelet therapies.

  2004cites this paper
• Antithrombotic effects of saratin on human atherosclerotic plaques

  2004cites this paper
• A modified Folts model or the original Folts model to evaluate new antithrombotics?

  2003cites this paper
• Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.

  2003cites this paper
• Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs.

  2003cites this paper
• Function‐modulating human monoclonal antibodies against platelet‐membrane receptors isolated from a phage‐display library

  2003cites this paper
• Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis

  2003cites this paper
• Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.

  2003cites this paper
• Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.

  2002cites this paper
• Pharmacokinetics and Pharmacodynamics of AJW200, a Humanized Monoclonal Antibody to von Willebrand Factor, in Monkeys

  2002cites this paper
• New Targets for Antithrombotic Drugs

  2002cites this paper
• Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y12) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ib&agr; Induced by Conditions of High Shear Rate

  2002cites this paper
• Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons.

  2002cites this paper
• Inhibition of Platelet Glycoprotein Ib, Glycoprotein IIb/IIIa, or Both by Monoclonal Antibodies Prevents Arterial Thrombosis in Baboons

  2002cites this paper
• Novel approaches to the treatment of thrombosis.

  2002cites this paper
• Two distinct mechanisms are involved in stent thrombosis under flow conditions.

  2001cites this paper
• Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation

  2001cites this paper
• Pharmacological control of platelet function.

  2001cites this paper
• Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs.

  2001cites this paper
• Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine 'Chuanxiong,' on platelet thrombus formation under high shear rates.

  2001cites this paper
• Two distinct mechanisms are involved in stent thrombosis under flow conditions

  2001cites this paper
• Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs

  2000cites this paper
• Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.

  2000cites this paper
• Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions.

  2000cites this paper
• Deposition and Neointima Formation After Balloon Injury in Guinea Pigs Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus

  2000cites this paper
• Flavone-8-acetic acid (Flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury In vivo.

  2000cites this paper
• Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction.

  2000cites this paper
• Plasma Concentration of von Willebrand Factor in Acute Myocardial Infarction

  2000cites this paper
• AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes.

  1999cites this paper
• Breaking the therapeutic barriers: New Strategies for acute coronary syndromes

  1999cites this paper
• Future directions in thrombolysis

  1999cites this paper
• Coronary thrombosis. Effects of blood flow on the mechanism of thrombus formation.

  1998cites this paper
• Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone.

  1997cites this paper
• Anti‐thrombotic effects and bleeding risk of AJvW‐2, a monoclonal antibody against human von Willebrand factor

  1997cites this paper
• Studies on the pathophysiology of thrombotic thrombocytopenic purpura.

  1997cites this paper
• Relative involvement of GPIb/IX-vWF axis and GPIIb/IIIa in thrombus growth at high shear rates in the guinea pig.

  1997cites this paper
• James Thornton Willerson, MD: a conversation with the editor. Interview by William Clifford Roberts.

  1997cites this paper
• The bernard-soulier syndrome.

  1997cites this paper
• James Thornton Willerson, MD: A Conversation With the Editor1

  1997cites this paper
• Differential effects of endothelin receptor activation on cyclic flow variations in rat mesenteric arteries.

  1997cites this paper
• Von Willebrand factor in patients evolving Q-wave versus non-Q-wave acute myocardial infarction.

  1996cites this paper
• Inhibition of cyclic flow variations by von Willebrand factor-glycoprotein Ib binding domain.

  1996cites this paper
• Guinea pig blood: a model for the pharmacologic modulation of the GPIb/IX-vWF axis.

  1996cites this paper
• A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea‐pigs

  1996cites this paper
• t-Plasminogen activator and von Willebrand factor in patients with unstable angina.

  1996cites this paper
• Sulfobacins A and B, novel von Willebrand factor receptor antagonists. I. Production, isolation, characterization and biological activities.

  1995cites this paper
• VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat.

  1995cites this paper
• To the editor : A modified Folts model or the original Folts model to evaluate new antithrombotics ?

  year unknowncites this paper